Intralesional administration of biological response modifiers in the treatment of localized cancer of the prostate: A feasibility study

Urology

Volumn 50, Issue 4, 1997, Pages 495-502

  Morales, Alvaro ^a,b   Johnston, Brenda ^a   Emerson, Laurel ^a   Heaton, Jeremy W P ^a  

^a QUEEN S UNIVERSITY   (Canada)

^b KINGSTON GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL RESPONSE MODIFIER; CIPROFLOXACIN; METRONIDAZOLE; RECOMBINANT ALPHA2B INTERFERON;

AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER LOCALIZATION; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; FATIGUE; FEVER; HEADACHE; HEMATURIA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOTHERAPY; INTRATUMORAL DRUG ADMINISTRATION; MALAISE; MALE; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; RECTAL DRUG ADMINISTRATION; SURGICAL APPROACH;

AGED; ANTINEOPLASTIC AGENTS; BIOLOGICAL RESPONSE MODIFIERS; FEASIBILITY STUDIES; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; PILOT PROJECTS; PROSTATIC NEOPLASMS;

EID: 0030860401     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(97)00402-0     Document Type: Article

References (26)

1. Parker SL, Tong T, Bolden S, and Wingo PA: Cancer statistics. CA Cancer J Clin 45: 5-27, 1977.
2. Albertsen PC, Fryback DG, and Storer BE: Long-term survival among men with conservatively treated localized prostate cancer. JAMA 274: 626-631, 1995.
3. Paulson DF: Impact of radical prostatectomy in the management of clinically localized disease. J Urol 152 (2 Pt 2): 1826-1830, 1994.
4. Lu-Yao GL, and Yao S: Population-based study of long-term survival in patients with clinically localised prostate cancer. Lancet 349: 906-910, 1977.
5. Chodak GW, Thisted RA, Gerber GS, Johansson JE, Adolfsson J, Jones GW, Chisholm GD, Moskovitz B, Livne PM, and Warner J: Results of conservative management of clinically localized prostate cancer. N Engl J Med 330: 242-248, 1994.
6. Connolly JA, Shinohara K, Presti JC Jr, and Carroll PR: Should cryosurgery be considered a therapeutic option in localized prostate cancer? Urol Clin North Am 23: 623-632, 1996.
7. Blaski JC, Radge H, Luse RW, Sylvester JE, Cavanagh W, and Grimm PD: Should brachytherapy be considered a therapeutic option in localized prostate cancer? Urol Clin North Am 23: 633-650, 1996.
8. Hanks GE: Long-term control of prostate cancer with radiation. Urol Clin North Am 23: 605-616, 1996.
9. Prostate cancer: current issues, new approaches. Proceedings of an international congress. Eur Urol 29(suppl 2):1-136, 1996.
10. Merrin C, Han T, Klein E, and Murphy GP: Immunotherapy of prostatic cancer with bacillus Calmette-Guérin and protein purified derivative. Preliminary results. Urology 2: 651-654, 1973.
11. Robinson MR, Rigby CC, Pugh RC, and Dummond DC: Adjuvant immunotherapy with BCG in carcinoma of the prostate. Br J Urol 49: 221-226, 1977.
12. Morales A, Nickel JC, and Manley P: The induction of controlled prostatic tissue necrosis by bacillus Calmette-Guérin derivatives. Urol Res 19: 35-38, 1991.
13. Morales A, Nickel JC, Downey J, Clark J, and van der Linden I: Immunotherapy of an experimental adenocarcinoma of the prostate. J Urol 153: 1706-1710, 1995.
14. Migliari R, Muscas G, Melis M, Solinas A, Sorgia M, and Usai E: Intraprostatic infiltration of β-interferon in advanced prostate cancer: PSA and PAP short term monitoring. Euro-American Conference on Urological Cancer, Abstract No. P44, 1993, Athens, September 1.
15. Matouschek E. Die behandlung des vesikorenalen refluxes durch transurethrale einspritzung von Teflon paste. Urologe [A] 20: 263-268, 1981.
16. Johnston BG: Clinical effects of Coley's vaccine: a controlled study. Cancer Chemother Rep 21: 19-41, 1962.
17. Grobb JJ, Colet AM, and Munoz MH: Treatment of basal cell carcinomas with intralesional interferon-alpha-2a. Lancet 1: 878-879, 1988.
18. Kirkwood JM, Ernstoff MS, Davis CA, Reiss M, Ferrciresi R, and Rudnick SA: Comparison of intramuscular and intravenous recombinant alpha-2 interferon in melanoma and other cancers. Ann Intern Med 103: 32-36, 1985.
19. Zbar B, Bernstein, ID, and Bartlett GL: Immunotherapy of cancer: regression of intradermal tumors and regression of growth of lymph node metastases after intralesional injection of Mycobacterium bovis. J Natl Cancer Inst 49: 119-130, 1972.
20. Schering-Plough Research Institute. Investigators Brochure. Intron® A (interferon alpha-2b, recombinant - injection), 1992.
21. Lievano G, Rubinstein M, Shaw M, and Guinan P: Bropirimine as neoadjuvant therapy is effective in a prostate cancer model (abstract). J Urol 155(suppl): 356A, 1996.
22. Israel K, Sanders BG, and Klein K: RRR-α-tocopherol succinate inhibits the proliferation of human prostatic tumor cells with defective cell cycle/differentiation pathways. Nutr Cancer 24: 161-169, 1995.
23. Trump DL: Retinoids in bladder, testis and prostate cancer: epidemiologic, pre-clinical and clinical observations. Leukemia 8(suppl 3):50-62, 1994.
24. Pang ASD, and Morales A: Chemoimmunoprophylaxis of an experimental bladder cancer with retinoids and BCG. J Urol 130: 166-170, 1983.
25. Bollag W: Retinoids and interferon: a new promising combination? Br J Haematol 79 (suppl 1): 87-91, 1991.
26. Morales A, and Chin J. MCW as an alternative to BCG in the treatment of CIS of bladder. J Urol 157: 214, 1997.